Apogee Therapeutics (APGE) Income towards Parent Company (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Income towards Parent Company data on file, last reported at -$74.1 million in Q1 2026.

• Income towards Parent Company for Q1 2026 came in at -$74.1 million, down 33.92% year-over-year; the trailing twelve-month figure through Mar 2026 was -$274.6 million (down 33.7% YoY), and the FY2025 annual result was -$255.8 million, down 40.46% from the prior year.
• Income towards Parent Company fell to -$74.1 million in Q1 2026 per APGE's latest filing, from -$69.4 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $43.6 million in Q4 2023 and troughed at -$74.1 million in Q1 2026.
• A 5-year average of -$34.2 million and a median of -$33.0 million in 2024 frame the typical range for Income towards Parent Company.
• On a YoY basis, Income towards Parent Company climbed as much as 409.46% in 2023 and fell as far as 939.92% in 2023.
• A 5-year view of Income towards Parent Company shows it stood at -$14.1 million in 2022, then soared by 409.46% to $43.6 million in 2023, then tumbled by 254.06% to -$67.2 million in 2024, then decreased by 3.23% to -$69.4 million in 2025, then fell by 6.81% to -$74.1 million in 2026.
• Business Quant data shows APGE's Income towards Parent Company at -$74.1 million in Q1 2026, -$69.4 million in Q4 2025, and -$65.0 million in Q3 2025.